Stilta

Stilta: Agentic AI for Patent Work

Stilta is an agentic AI platform built for patent and intellectual-property analysis. It runs the core analyses that IP teams and law firms rely on — invalidity, infringement, and freedom-to-operate (FTO) — and returns source-cited evidence drawn from patents, scientific literature, file wrappers, and web archives. Rather than a general legal assistant, it is tuned for the recall and defensibility that patent work demands.

The output is meant to be litigation-grade: claim charts and FTO opinions assembled in minutes, with one-click verification back to the underlying sources.

Key Features

• Invalidity, infringement, and freedom-to-operate analysis
• Source-cited evidence across patents, journals, and archives
• Full-text patent analysis tuned for high recall
• Portfolio-scale infringement mapping
• Defensible claim charts and FTO opinions
• One-click source verification

Ideal Use Case

Stilta fits patent attorneys, IP litigators, and corporate IP teams who need thorough, citable prior-art and infringement analysis without the manual hours those reviews normally take. It suits high-stakes IP work where every conclusion must trace back to a source.

How Stilta differentiates

Stilta specializes in patent and IP analysis with a focus on recall and source-cited, defensible output, rather than a general-purpose legal chatbot. It raised a $10.5M seed led by Andreessen Horowitz, with backing from Microsoft, NVIDIA, and Y Combinator, and lists customers including KUKA and Mannheimer Swartling.

FAQ

What is Stilta? An agentic AI platform for patent work — invalidity, infringement, and freedom-to-operate analysis with cited evidence.

Who is it for? Patent attorneys, IP litigators, and corporate IP teams.

Is the output verifiable? Yes — Stilta cites sources and offers one-click verification to the underlying documents.

Who backs Stilta? A $10.5M seed led by a16z, with Microsoft, NVIDIA, and Y Combinator.

tl;dr

Stilta is an agentic AI platform for patent invalidity, infringement, and freedom-to-operate analysis with source-cited evidence, backed by a $10.5M a16z seed and used by KUKA and Mannheimer Swartling.